Can Novel Anticoagulants Reduce Thrombosis Without Increasing Bleeding – JTH
Journal of Thrombosis and Haemostasis (JTH) shared a post on LinkedIn about a recent article by Surasak Wichaiyo, published in Journal of Thrombosis and Haemostasis, adding:
“Pharmacology of anticoagulants: from heparin to novel target-specific agents.
This review delineates the pharmacology of currently available anticoagulants (heparins, warfarin, and direct oral anticoagulants) alongside investigational agents.
Factor XI and factor XII inhibitors emerge as targets that may uncouple antithrombotic efficacy from bleeding risk, with several FXI inhibitors now in phase II and III trials.”
Title: Pharmacology of anticoagulants: from heparin to novel target-specific agents
Authors: Surasak Wichaiyo
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 7, 2026, 15:09Kashis Gupta: Excited to Share My AI/ML Project – Anemia Fusion Net!
-
Sep 7, 2026, 15:08Adam Urato: The Platelet Paradox of SSRIs
-
Sep 7, 2026, 15:00Haroon Gul Khan: Why Critical Reading Matters in Medical Education
-
Sep 7, 2026, 14:59Ahmed Mahmoud: Vitamin B12 Deficiency Can Present Far Beyond Fatigue and Macrocytic Anemia
-
Sep 7, 2026, 14:49Abid Husain: Tirzepatide Drives Broad Improvements in Cardiovascular Risk Biomarkers
-
Sep 7, 2026, 14:46Shabnam Arsiwala: Did You Know there are Multiple Types of Sickle Cell Disease?
-
Sep 7, 2026, 14:46Ahmed Bennis: Angiotensin II and Platelet PAR4 Activation in Hypertension
-
Sep 7, 2026, 14:42Scott Isaacs: Obesity Is Not Only a Cardiometabolic Disease
-
Sep 7, 2026, 14:41Chayakrit Krittanawong: Precision Anticoagulation in the Cath Lab – What Happens when the Patient Doesn’t Look like the Trial?